Clinical Trial Update: Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating Botox for thyroid-related upper eyelid retraction in Graves' ophthalmopathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: University of Toronto | Conditions: Graves Ophthalmopathy | Phase 4 | Status: WITHDRAWN